Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius AG (SSSGY) reported a strong start to 2026 with sales revenue increasing by 7.5% in constant currencies, reaching EUR899 million.
- The Bioprocess Solutions division saw an 8.1% increase in sales, driven by high-margin recurring consumables business.
- Lab Products & Services division achieved a 4.9% sales increase in constant currencies, supported by the MatTek acquisition.
- The company launched innovative products like the Eveo cell therapy manufacturing platform, which enhances production efficiency and reduces cycle times.
- Sartorius AG (SSSGY) maintained a solid equity ratio of 39.4% and continued to make progress on deleveraging, with net debt decreasing slightly to EUR3.727 billion.
- Equipment sales were softer in Q1 due to delivery schedules, although improvement is expected in Q2.
- The underlying EBITDA margin remained flat at 29.7%, impacted by mix effects and tariff impacts.
- Lab Products & Services reported a slight sales decline of 0.6% in reported figures due to FX effects.
- The company faces geopolitical and macroeconomic uncertainties, particularly in the Middle East, which could impact future performance.
- Sartorius AG (SSSGY) anticipates a headwind of approximately minus 2 percentage points from foreign exchange effects for the full year.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech conference call and live webcast on Q1 2026. I'm your chorus call operator. (Operator Instructions). I would now like to turn the conference over to Petra Muller, Head of Investor Relations of Sartorius. Please go ahead.
Thank you. Hello, and a welcome also from my side. I'm joined today by our CEO, Michael Grosse; Florian Funck, our CFO, by Rene Faber, Head of the Bioprocessing division and CEO of Sartorius Biotech; and by Alexandra Gatzemeyer, Head of our LPS division.
As always, we will start with prepared remarks followed by the Q&A session. As the call is scheduled to one hour, please limit your question to one so that as many participants as possible can take part. Please note that management's comments during this call will include forward-looking statements that involve risks and uncertainties. For a discussion of risk factors, I encourage you to review the safe harbor statement contained in today's press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
